Biohaven Books A $396 Million Irish Tax Asset, Then Reserves All Of It
The drugmaker says licensing payments from SK Biopharmaceuticals could later let it release a significant part of the reserve.
Biohaven, a biopharmaceutical company developing treatments in immunology, neuroscience and oncology, recorded a $396.0 million deferred tax asset after moving intellectual property to its Irish subsidiary in August, then set up a full valuation allowance against it, according to its 10-Q filed Thursday. The company said payments under its SK Biopharmaceuticals license could eventually justify releasing a significant portion of that reserve.
A full reserve, with a path to release
The asset reflects a step-up in tax basis under Irish tax law. As of September 30, Biohaven concluded it was more likely than not that the asset would not be realized, so it reserved all of it.
The company wrote that it anticipates potential payments from the SKBP license could produce future earnings, and that sufficient positive evidence may allow it to conclude a significant portion of the Irish allowance is no longer needed. A release would lower income tax expense in the period it is recorded, though timing and amount depend on the profitability it actually achieves.
The prior quarter's 10-Q carried only a general full valuation allowance statement and no Irish transfer.
The SKBP money behind the evidence
Under the August license, SKBP will pay a $400.0 million upfront fee: $350.0 million at closing and $50.0 million a year later. Milestones could add up to $150.0 million, along with royalties on opakalim sales. Antitrust clearance came October 28, so only the remaining closing conditions stand.
At closing, SKBP would also assume up to $245.0 million of milestone obligations to Knopp Biosciences: $185.0 million tied to opakalim approvals and up to $60.0 million for other Kv7 products.
In October, Ono licensed Biohaven's IgG degraders for Japan, South Korea, Taiwan and Southeast Asia. Ono paid $80.0 million upfront and owes another $20.0 million if it elects to continue after stability testing.
Thin cash, a partial clinical hold
Biohaven has no product revenue. At September 30 it held $95.8 million in cash and equivalents and $65.4 million in marketable securities, against $250.0 million of senior secured notes outstanding. Its market value was $2.3 billion at Thursday's report.
A September 4 FDA partial clinical hold halts new enrollment in opakalim studies. Dosing of enrolled patients continues, and the company says RISE 3 topline data remain on track for the second half of 2026. The company said all related data was disclosed to SKBP before the license was signed.
The tax reserve and the $350.0 million closing payment now hang on the same event: the SKBP deal closing.
Sources
- 10-Q Filing — Biohaven (BHVN) — SEC EDGAR
- 10-Q Filing — Biohaven (BHVN), Q2 FY2026 filed 2026-08-10 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, a2026q3bhvnearningsprex991.htm) — Biohaven, filed 2026-10-29 — SEC EDGAR
- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance — Yahoo Finance
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade — Yahoo Finance
- Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy — Yahoo Finance
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results — prnewswire.com
